Sarcopenia is risk factor for prognosis of patients with biliopancreatic diseases.

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hepatobiliary & Pancreatic Diseases International Pub Date : 2025-09-22 DOI:10.1016/j.hbpd.2025.09.005

Tomoya Emori, Reiko Ashida, Masayuki Kitano

{"title":"Sarcopenia is risk factor for prognosis of patients with biliopancreatic diseases.","authors":"Tomoya Emori, Reiko Ashida, Masayuki Kitano","doi":"10.1016/j.hbpd.2025.09.005","DOIUrl":null,"url":null,"abstract":"<p><p>The prevalence of sarcopenia tends to be high in patients with biliopancreatic disease. Sarcopenia is a risk factor of poor prognosis in patients with acute and chronic pancreatitis and biliary tract and pancreatic cancer. Several studies have suggested that sarcopenia may be a risk factor for perioperative complications and decreased recurrence-free or overall survival in patients with biliary tract and pancreatic cancer after surgery. Sarcopenia in biliary tract and pancreatic cancer may also increase chemotherapy-induced toxicities and worsen quality of life and survival in neoadjuvant or palliative chemotherapy. Moreover, sarcopenia is a risk factor for biliary stent occlusion in patients with malignant biliary obstruction, predictors of the efficacy of endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) for pain relief, EUS-guided drainage, and endoscopic necrosectomy for walled-off necrosis (WON). Diagnosis of sarcopenia prior to the treatment of biliopancreatic diseases and endoscopy may predict treatment efficacy, and appropriate nutritional and exercise therapy improve therapeutic outcomes of patients with biliopancreatic diseases.</p>","PeriodicalId":55059,"journal":{"name":"Hepatobiliary & Pancreatic Diseases International","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatobiliary & Pancreatic Diseases International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.hbpd.2025.09.005","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The prevalence of sarcopenia tends to be high in patients with biliopancreatic disease. Sarcopenia is a risk factor of poor prognosis in patients with acute and chronic pancreatitis and biliary tract and pancreatic cancer. Several studies have suggested that sarcopenia may be a risk factor for perioperative complications and decreased recurrence-free or overall survival in patients with biliary tract and pancreatic cancer after surgery. Sarcopenia in biliary tract and pancreatic cancer may also increase chemotherapy-induced toxicities and worsen quality of life and survival in neoadjuvant or palliative chemotherapy. Moreover, sarcopenia is a risk factor for biliary stent occlusion in patients with malignant biliary obstruction, predictors of the efficacy of endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) for pain relief, EUS-guided drainage, and endoscopic necrosectomy for walled-off necrosis (WON). Diagnosis of sarcopenia prior to the treatment of biliopancreatic diseases and endoscopy may predict treatment efficacy, and appropriate nutritional and exercise therapy improve therapeutic outcomes of patients with biliopancreatic diseases.

查看原文本刊更多论文

肌少症是影响胆胰疾病患者预后的危险因素。

胆道胰腺疾病患者中肌肉减少症的患病率往往较高。骨骼肌减少症是急慢性胰腺炎、胆道及胰腺癌患者预后不良的危险因素。一些研究表明，肌肉减少症可能是胆道和胰腺癌患者手术后围手术期并发症和减少无复发或总生存期的危险因素。胆道和胰腺癌的肌肉减少症也可能增加化疗引起的毒性，并使新辅助或姑息性化疗的生活质量和生存恶化。此外，肌少症是恶性胆道梗阻患者胆道支架闭塞的危险因素，是内镜下超声引导下腹腔丛神经松解术（EUS-CPN）缓解疼痛、eus引导下引流和内镜下坏死切除术治疗壁闭塞性坏死（WON）疗效的预测因素。胆道胰腺疾病治疗前的肌肉减少症诊断和内镜检查可以预测治疗效果，适当的营养和运动治疗可以改善胆道胰腺疾病患者的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatobiliary & Pancreatic Diseases International 医学-胃肠肝病学

CiteScore

5.40

自引率

6.10%

发文量

152

审稿时长

3.0 months

期刊介绍： Hepatobiliary & Pancreatic Diseases International (HBPD INT) (ISSN 1499-3872 / CN 33-1391/R) a bimonthly journal published by First Affiliated Hospital, Zhejiang University School of Medicine, China. It publishes peer-reviewed original papers, reviews and editorials concerned with clinical practice and research in the fields of hepatobiliary and pancreatic diseases. Papers cover the medical, surgical, radiological, pathological, biochemical, physiological and historical aspects of the subject areas under the headings Liver, Biliary, Pancreas, Transplantation, Research, Special Reports, Editorials, Review Articles, Brief Communications, Clinical Summary, Clinical Images and Case Reports. It also deals with the basic sciences and experimental work. The journal is abstracted and indexed in SCI-E, IM/MEDLINE, EMBASE/EM, CA, Scopus, ScienceDirect, etc.